Asmarawati, T.P.; Widyatama, F.S.; Notobroto, H.B.; Nasronudin, N.; Sugai, M.; Kuntaman, K.
Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Bacteremia Among Hospitalized Patients. Antibiotics 2025, 14, 882.
https://doi.org/10.3390/antibiotics14090882
AMA Style
Asmarawati TP, Widyatama FS, Notobroto HB, Nasronudin N, Sugai M, Kuntaman K.
Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Bacteremia Among Hospitalized Patients. Antibiotics. 2025; 14(9):882.
https://doi.org/10.3390/antibiotics14090882
Chicago/Turabian Style
Asmarawati, Tri Pudy, Fikri Sasongko Widyatama, Hari Basuki Notobroto, Nasronudin Nasronudin, Motoyuki Sugai, and Kuntaman Kuntaman.
2025. "Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Bacteremia Among Hospitalized Patients" Antibiotics 14, no. 9: 882.
https://doi.org/10.3390/antibiotics14090882
APA Style
Asmarawati, T. P., Widyatama, F. S., Notobroto, H. B., Nasronudin, N., Sugai, M., & Kuntaman, K.
(2025). Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Bacteremia Among Hospitalized Patients. Antibiotics, 14(9), 882.
https://doi.org/10.3390/antibiotics14090882
